The latest price target for Black Diamond Therapeutic (NASDAQ:BDTX) was reported by HC Wainwright & Co. on November 6, 2024. The analyst firm set a price target for $11.00 expecting BDTX to rise to within 12 months (a possible 386.75% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Black Diamond Therapeutic (NASDAQ:BDTX) was provided by HC Wainwright & Co., and Black Diamond Therapeutic reiterated their buy rating.

The last upgrade for Black Diamond Therapeutics Inc happened on June 30, 2023 when Stifel raised their price target to $10. Stifel previously had a hold for Black Diamond Therapeutics Inc.

The last downgrade for Black Diamond Therapeutics Inc happened on March 29, 2022 when Wedbush changed their price target from N/A to N/A for Black Diamond Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Black Diamond Therapeutic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Black Diamond Therapeutic was filed on November 6, 2024 so you should expect the next rating to be made available sometime around November 6, 2025.

While ratings are subjective and will change, the latest Black Diamond Therapeutic (BDTX) rating was a reiterated with a price target of $11.00 to $11.00. The current price Black Diamond Therapeutic (BDTX) is trading at is $2.26, which is out of the analyst’s predicted range.